Aelin Therapeutics
About
Aelin Therapeutics is a provider of a biotherapeutics platform technology called pept-ins that are intended to harnesses.
- Belgium,Wisconsin,United States
- 11 - 50
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- €27M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2017
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Aelin Therapeutics, a privately held Belgian biotherapeutics company.Aelin Therapeutics is founded by VIB and its partner universities KU Leuven, VUB and UGent, based on the groundbreaking work of renowned structural biologists Prof Joost Schymkowitz and Prof Frederic Rousseau. The company is based on a very comprehensive preclinical Proof of Concept data package illustrating different applications of the technology such as in bacteria and cancer cells, but also in fungi, viruses and plant cells, with publications in high impact journals including Science. The Pept-in technology allows for the rational design of novel biotherapeutics and differentiates itself from any other therapeutic modality through its unique mode of action, its designability and intracellular target space out of reach for typical small molecule or antibody approaches.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 11, 2017 | Series A | €27M | 5 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Boehringer Ingelheim Venture Fund
|
— | Series A |
Fund+
|
— | Series A |
LSP BioVentures
|
— | Series A |
Novartis Venture Fund
|
— | Series A |
PMV
|
— | Series A |
Employee Profiles
